Workflow
医药行业创新药周报：2024年6月第四周创新药周报（附小专题HIV-1 capsid靶点研发概况）
Southwest Securities·2024-06-24 09:00

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry as of June 23, 2024 [1]. Core Insights - The innovation drug sector in both A-shares and Hong Kong stocks experienced a decline, with A-shares down 4.32% and Hong Kong stocks down 5.88% in the fourth week of June 2024 [2][15]. - The report highlights that 14 stocks rose while 45 stocks fell in the innovation drug sector during the same week, with notable gainers including Frontline Bio-U (+15.82%) and Nanjing New Pharmaceutical (+8.85%) [2][15]. - Over the past six months, A-shares in the innovation drug sector have cumulatively decreased by 4.40%, underperforming the CSI 300 index by 7.44 percentage points [2][16]. - The report also notes that the XBI index in the U.S. increased by 2.21% during the same week, with a cumulative increase of 1.7% over the past six months [2][20]. Summary by Sections 1. Market Performance - A total of 14 stocks in the innovation drug sector rose, while 45 fell, with the A-share innovation drug sector down 4.32% [2][15]. - The Hong Kong innovation drug sector fell by 5.88%, underperforming the Hang Seng Index by 6.36 percentage points [2][18]. - The XBI index in the U.S. rose by 2.21% during the week [2][20]. 2. New Drug Approvals - In June, 7 new drugs were approved in China, with 3 new indications approved this week [3][21]. - The U.S. saw 5 NDA approvals and 1 BLA approval in June, with 2 NDA approvals and 1 BLA approval this week [3][26]. - No new drugs were approved in Europe or Japan during June [3][28][30]. 3. Key Drug Developments - The report discusses the progress of key innovative drugs, including the approval of lenacapavir for HIV-1 prevention, which showed a 100% efficacy rate in a key trial [4]. - The report also highlights the ongoing development of GLP-1 receptor agonists for diabetes and obesity, with multiple drugs in various stages of clinical trials [8][11]. 4. Clinical Trials - A total of 54 clinical trials were publicly announced in China this week, including 22 Phase I trials, 10 Phase II trials, and 21 Phase III trials [21][24].